scholarly journals Novel Ferrocene Derivatives Induce G0/G1 Cell Cycle Arrest and Apoptosis through the Mitochondrial Pathway in Human Hepatocellular Carcinoma

2021 ◽  
Vol 22 (6) ◽  
pp. 3097
Author(s):  
Jianrong Zheng ◽  
Liao Zeng ◽  
Mingqing Tang ◽  
Hongjun Lin ◽  
Chao Pi ◽  
...  

In this study, detailed information on hepatocellular carcinoma (HCC) cells (HepG-2, SMMC-7721, and HuH-7) and normal human liver cell L02 treated by ferrocene derivatives (compounds 1, 2 and 3) is provided. The cell viability assay showed that compound 1 presented the most potent and selective anti-HCC activity. Further mechanism study indicated that the proliferation inhibition effect of compound 1 was associated with the cycle arrest at the G0/G1 phase and downregulation of cyclin D1/CDK4. Moreover, compound 1 could induce apoptosis in HCC cells by loss of mitochondrial membrane potential (ΔΨm), accumulation of reactive oxygen species (ROS), decrease in Bcl-2, increase in BAX and Bad, translocation of Cytochrome c, activation of Caspase-9, -3, and cleavage of PARP. These results indicated that compound 1 would be a promising candidate against HCC through G0/G1 cell cycle arrest-related proliferation inhibition and mitochondrial pathway-dependent apoptosis.

2020 ◽  
Author(s):  
Kija Malale ◽  
Jili Fu ◽  
Liewang Qiu ◽  
Ke Zhan ◽  
Xiuni Gan ◽  
...  

Abstract Background Sorafenib is the only targeted therapy promising to improve the prognosis of patients with advanced hepatocellular carcinoma (HCC), but its long-term clinical efficacy is limited due to chemotherapy resistance. The lack of a full understanding of the anti-tumor mechanism of sorafenib in HCC is attributed to the difficulties in understanding the mechanism of drug resistance. In recent years, a large number of preclinical and clinical data have confirmed the catalytic role of aquaporin-3 (AQP3) in a variety of tumors including HCC, but none of the studies reported the regulatory mechanism of AQP3 during sorafenib treatment. This study examined the effect of sorafenib on the expression of AQP3 in HCC cells and determined whether the effect is associated with cell proliferation inhibition, cell cycle arrest, and increased apoptotic. Methods mRNA and protein levels of AQP3 in hepatoma cell lines exposed to sorafenib or UO126 were detected via real-time quantitative polymerase chain reaction (qPCR) and western blotting, respectively. The effect of AQP3 expression changes on cell proliferation, cell cycle and apoptosis were determined by cell counting kit-8 (CCK-8) and flow cytometry. In addition, western blotting detected proteins involved in the regulation of proliferation and cell cycle progression. Results The results showed that AQP3 was down-regulated in all cell lines exposed to sorafenib or UO126 in a concentration dependent manner. The downregulation of AQP3 successfully inhibited cell proliferation, induced cell cycle arrest and increased cell apoptosis, while the reverse was true when AQP3 was overexpressed. Western blotting results showed that in AQP3 knockdown cells, the amounts of Erk, Akt, p53, p-Erk, p-Akt and cyclin-dependent kinase 2 (CDK2) decreased, while the amounts of cyclin-dependent kinase 4 (CDK4), p21 and p-p53 increased. Conclusion This study found that sorafenib may inhibit proliferation, induce cell cycle arrest, and increase apoptosis of HCC cells by regulating the expression of AQP3.


RSC Advances ◽  
2017 ◽  
Vol 7 (34) ◽  
pp. 21342-21351 ◽  
Author(s):  
Fei Long ◽  
Chengyong Dong ◽  
Keqiu Jiang ◽  
Yakun Xu ◽  
Xinming Chi ◽  
...  

Proposed model elucidating the role of MT in regulating the proliferation of hepatocellular carcinoma (HCC) cells treated with sorafenib.


2021 ◽  
Vol 11 (10) ◽  
pp. 983
Author(s):  
Han Ki Lee ◽  
Heui Min Lim ◽  
See-Hyoung Park ◽  
Myeong Jin Nam

Background: CRISPR/Cas9 system is a prokaryotic adaptive immune response system that uses noncoding RNAs to guide the Cas9 nuclease to induce site-specific DNA cleavage. Hepatocyte growth factor (HGF) is a well-known growth factor that plays a crucial role in cell growth and organ development. According to recent studies, it has been reported that HGF promoted growth of hepatocellular carcinoma (HCC) cells. Here, we investigated the apoptotic effects in HCC cells. Methods: Crispr-HGF plasmid was constructed using GeneArt CRISPR Nuclease Vector. pMex-HGF plasmid that targets HGF overexpressing gene were designed with pMex-neo plasmid. We performed real time-polymerase chain reaction to measure the expression of HGF mRNA. We performed cell counting assay and colony formation assay to evaluate cell proliferation. We also carried out migration assay and invasion assay to reveal the inhibitory effects of Crispr-HGF in HCC cells. Furthermore, we performed cell cycle analysis to detect transfection of Crispr-HGF induced cell cycle arrest. Collectively, we performed annexin V/PI staining assay and Western blot assay. Results: In Crispr-HGF-transfected group, the mRNA expression levels of HGF were markedly downregulated compared to pMex-HGF-transfected group. Moreover, Crispr-HGF inhibited cell viability in HCC cells. We detected that wound area and invaded cells were suppressed in Crispr-HGF-transfected cells. The results showed that transfection of Crispr-HGF induced cell cycle arrest and apoptosis in HCC cells. Expression of the phosphorylation of mitogen activated protein kinases and c-Met protein was regulated in Crispr-HGF-transfected group. Interestingly, we found that the expression of HGF protein in conditioned media significantly decreased in Crispr-HGF-transfected group. Conclusions: Taken together, we found that inhibition of HGF through transfection of Crispr-HGF suppressed cell proliferation and induced apoptotic effects in HCC Huh7 and Hep3B cells.


Pharmaceutics ◽  
2018 ◽  
Vol 10 (4) ◽  
pp. 198 ◽  
Author(s):  
Bee Tan ◽  
Mohd Norhaizan ◽  
Lee Chan

Magnetic iron oxide nanoparticles are among the most useful metal nanoparticles in biomedical applications. A previous study had confirmed that phytic acid-chitosan-iron oxide nanocomposite (Phy-CS-MNP) exhibited antiproliferative activity towards human colorectal cancer (HT-29) cells. Hence, in this work, we explored the in vitro cytotoxicity activity and mechanistic action of Phy-CS-MNP nanocomposite in modulating gene and protein expression profiles in HT-29 cell lines. Cell cycle arrest and apoptosis were evaluated by NovoCyte Flow Cytometer. The mRNA changes (cyclin-dependent kinase 4 (Cdk4), vascular endothelial growth factor A (VEGFA), c-Jun N-terminal kinase 1 (JNK1), inducible nitric oxide synthase (iNOS), and matrix metallopeptidase 9 (MMP9)) and protein expression (nuclear factor-kappa B (NF-κB) and cytochrome c) were assessed by quantitative real-time polymerase chain reaction (PCR) and western blotting, respectively. The data from our study demonstrated that treatment with Phy-CS-MNP nanocomposite triggered apoptosis and G0/G1 cell cycle arrest. The transcriptional activity of JNK1 and iNOS was upregulated after treatment with 90 μg/mL Phy-CS-MNP nanocomposite. Our results suggested that Phy-CS-MNP nanocomposite induced apoptosis and cell cycle arrest via an intrinsic mitochondrial pathway through modulation of Bax and Bcl-2 and the release of cytochrome c from the mitochondria into the cytosol.


Sign in / Sign up

Export Citation Format

Share Document